At a glance
ClinicalIndex Comparison RecordN/ACompleted· 352 enrolled
Drug / intervention
MYNX CONTROL™ Venous Vascular Closure Device 6F-12Fdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Prospective, Randomized, Controlled, Open Label Trial to Evaluate the Safety and Efficacy of Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression in Patients Who Have Undergone Endovascular Procedures Utilizing up to 12F Procedural Sheaths
In Brief
A clinical study evaluating MYNX CONTROL™ Venous Vascular Closure Device 6F-12F for Venous Vascular Closure. Completed, enrolled 352 participants across 14 sites.
Detailed Summary
ReliaSeal is a clinical trial designed to evaluate safety and efficacy of use of MYNX CONTROL™ Venous Vascular Closure Device 6F-12F vs. manual compression to seal femoral access sites in patients who have undergone endovascular procedures utilizing up to 12F procedural sheaths in one or both limbs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Vascular Closure
CountriesUnited States
CollaboratorsNAMSA
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartAug 2022
First PostedSep 2022
Primary CompletionJul 2023
TodayJul 2026
First PostedSep 26, 2022
Enrollment StartAug 30, 2022
Primary CompletionJul 11, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.8 years ago
Interventions
MYNX CONTROL™ Venous Vascular Closure Device 6F-12Fdevice
Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.